Replies to post #15749 on Radient Pharmaceuticals Corporation fka RXPC

[Gold Seeker]

Mike, the last reported sales were for the 4th quarter of 2011 and that was $56,000.

That certainly was not enough sales to keep Radient in business who was burning more than a million per quarter.

MacLellan recently stated to an investor in an email that production had increased. Even if production doubled, it would never come close to covering operating expenses.

Onko Sure is just not a viable product to keep Radient in business nor an asset any company would want to buy. Chinese manufacturing costs are very low and the Chinese company manufacturing the generic test has hundreds of other products also.